7th Expanded Access Progammes World Congress 2024 Americas
Thursday 14th - Friday 15th November 2024
Paradigm Global Events is very pleased to welcome you to our upcoming 7th Expanded Access Programmes World Congress 2024 Americas.
Early access programmes offer ethical, compliant and controlled mechanisms of access to investigational medicinal products (IMP) outside of the clinical trial space and before marketing and authorisation.
Expanded Access also known by other terms such as compassionate use, early access, managed access, named-patient access, or pre-approval access is a potential pathway for a patient with an immediately life-threatening illness or severely debilitating disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) before they are reviewed and approved by a regulatory authority. When it is not possible for a patient to participate in a clinical trial and all other available medical options have been exhausted, the patient’s physician may seek special access to investigational medicine outside of the clinical trial setting. As investigational drugs have not yet received regulatory approval, it is very important to remember that their potential risks and benefits are not yet established. In general the person and his or her doctor must apply for access to the investigational product, the company has to choose to cooperate, and the medicines regulatory agency needs to agree that the risks and possible benefits of the drug or device are understood well enough to determine if putting the person at risk has sufficient potential benefit.
With patients thoroughly becoming knowledgeable, Pharmaceutical companies are bound to receive unsought request. However, there are challenges and obstacles such as diverse regulatory landscape, logistical differences, and complexities from planning an application to approval and implementation. Sponsors need to plan carefully before undertaking an Expanded Access Programme so that they have the resources, processes, and tools in place to support the inevitable demand.
EAPs promises huge potential to all stakeholders involved, from patients who obtained the medicines early to the pharmaceutical companies who provides it. Companies who invest in them may see considerable benefit in terms of relationship building with key stakeholders, such as patients, advocacy groups, scientists and regulators, as well as launch preparedness.
The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key expert speakers with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts in obtaining the much needed access to these therapies for life changing treatment.
We look forward to meeting you at the Congress!
Sincerely yours,
Jocelyn Raguindin
Conference Director
Paradigm Global Events
GAIN THE LATEST INSIGHTS ON:
- Understanding the varying regulatory landscape, policies and guidelines to ensure a smooth execution of the programme
- The benefits and issues surrounding expanded access programme
- Criteria that must be met to authorize expanded access use, requirements for expanded access submissions
- The current compassionate use, or expanded access-related mechanisms
- Understanding operational complexities, best practices and strategies in running a global EAP
- Current trends and lessons learned from successful implementation
- Successfully navigating supply and logistical intricacies
- Incorporating patient voice from early planning to ensure a patient-centric access programme
- Robust data collection strategies for informed decision making
- Real-world data challenges and solutions
- Engaging representatives from all stakeholder groups to understand their perspective and
expectations of the programme
WHO SHOULD ATTEND?
This Congress will provide information to pharmaceutical and biotech companies, researchers, physicians, institutional review boards (IRBs), patient organizations and advocates, and regulatory agencies about the implementation of expanded access to investigational drugs.
Network with representatives involved in the following areas:
- Expanded Access
- Managed Access
- Early Access
- Market Access
- Medical Affairs
- Regulatory Affairs and Policy
- Patient Support and Patient Engagement
- Corporate Development
- RWE, and Data Management
- Quality and Compliance
- Clinical Development Programme
- Management
- Supply Chain Management
- Patient Access
- Clinical Research
- Sourcing and Logistics
- Consulting
- And much more…
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
MACRO OUTLOOK & CURRENT TRENDS
- When should companies consider the idea of Early Access Programmes?
- Understanding the challenges in running a global EAP
- Navigating country specific framework and requirements
- Addressing challenges on patients demands and supply
- Positive impact of EAP on patients with serious, immediately life-threatening, or rapidly debilitating diseases
Moderator:
Panelist:
Elsa Luna, Director, Expanded Access Operations, Pfizer
- Planning and designing for expanded access programs early can be difficult. This panel explores how pharma and biotech can work with Patient Advocacy Groups and Research Consortiums to ensure that the patient voice is part of early planning, and how digital communities can facilitate early planning and
awareness of expanded access programs.
- What is expanded access and when do we use it?
- How do we plan for expanded access?
- Who needs to be involved with expanded access and what is the key to its success?
- What are the means to get the medicine to the patient?
- Country Specific Regulatory Pathways
- Practical Challenges and Solutions in PTA
- Unique Operational Considerations for PTA
Jennifer Grigonis, Sr. Director Business Development EAP, Bionical Emas
Tori Rizk, Associate Portfolio Director, Bionical Emas
Patrick Raletz, Project Manager EAP, Bionical Emas
Juan Rosario, Project Manager EAP, Bionical Emas
- In an era where ‘real-world data’ is increasing of interest, what are the limitations?
- Data collection within early access programs in various regions
- Ethical considerations and operational challenges in conducting data collection
- Benefits of collecting RWD within early access programs
CHALLENGES & POTENTIALS
- Opening an EAP without Vendor Support
- Considering Stakeholder Expectations
- Managing Resource Limitations
Amber Bifolck Fisher, Senior Clinical Research Manager, Expanded Access, Kura Oncology
- Building your EAP with a ‘site-first’ approach
- Educating sites on their roles and responsibilities in an EAP
- Ensuring a clear communication plan to support sites in an expedited manner
- Case study demonstrating the importance of site management
- Introduction to EAP and their differences
- When does the implementation of the Early Access programme be considered?
- What are the numerous challenges faced in the implementation of EAPs?
- Key considerations for the successful implementation of early access program
Christine Istanboulian, Global Medical Operations , Early Access Programs, Sanofi
- Recognizing the importance of patient-centered approaches.
- Advocating for equitable access to medications
- Prioritizing empathy and understanding in healthcare decision-making.
Chisa Nosamiefan, Co-founder, The Labalaba Foundation for Lupus
- How should societies address a request for a single patient in need when a drug is not being made broadly available?
- Could sponsors or governments ethically say yes to one person and no to others?
- Who should be deciding which patients will live?
- Drivers of early access programmes
- Setting up a clear perspective and expectations of the programme
- Streamlining process and ensuring early access of medicinal products to patients
- How regulators and reimbursement agencies can work together to help ensure that patients are able to access life changing medicines as soon as it is safe for them to do so?
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
BREAKING DOWN BARRIERS TO PATIENT ACCESS
- Value of patient engagement in Early Access Programmes
- How important is engaging patient at the earliest stage in research and development
- The need for a continuous meaningful dialogue between stakeholders to establish an effective working relationship
- What are the best practices and ethics behind a successful early access programme?
- Knowing what motivates the stakeholders within early access
- Sustaining purposeful patient engagement across the lifecycle of medicines
Moderator:
Panelist:
- The need for expanded access in the rare disease community
- How increase awareness can accelerate access
- Incorporating patient stories and lived experience to drive change
- The ethical imperative for gene therapy companies to proactively develop expanded access policies
- Obstacles developers face in providing expanded access to gene therapy products
- Conditions with limited windows for treatment deserve special consideration in expanded access
- Advancing Equity
- Inclusive Communication
- Culturally Effective
- Decision Making
- Voices of Diversity
- Understanding the disease area and impact on the patient and family
- When to engage with patient advocacy organisations and the value they can bring
- Best practices to ensure patients are partners in your clinical development process
Senior Representative, Pulse Inforframe
- Considerations in planning EAP’s with patient in mind
- Engaging with patient and advocacy groups early in development for well informed decision
- Strategies to ensure patients voice is incorporated in development discussions
- When to consider EAP and when it might not be the right thing to do for the community
MULTI-STAKEHOLDER APPROACH & COLLABORATION
- Determining if an EAP is right for your therapy and company
- Internal stakeholders – all internal functions
- External stakeholders – expansion from Physicians and Regulators to all stakeholders (Payors, Reviewers, Patients and others)
- Consistent management through concept, initiation, management and closure
- Different approaches needed for Gene and highly specialist therapies
- Transferring the patient to a treatment site in a different country
- Interaction between pharmaceutical companies and healthcare providers could foster the development of new medicines which will ultimately benefit patients.
- Would this enhance technological innovation, fosters knowledge creation, aids disease control, and reduces polypharmacy issues?
- Guidelines to help professionals navigate the opposing explanations of interactions with pharmaceutical companies
- Drivers of early access programmes
- Setting up a clear perspective and expectations of the programme
- Streamlining process and ensuring early access of medicinal products to patients
- How regulators and reimbursement agencies can work together to help ensure that patients are able to access life changing medicines as soon as it is safe for them to do so?
- Deep-dive into the reality of healthcare access around the world
- Streamlining the process and navigating early access regulations globally
- The need for a continuous meaningful dialogue between stakeholders to establish an effective working relationship
- What are the best practices and ethics behind a successful early access programme?
- What does the future of health access look like?
Panelists:
END OF CONFERENCE
